Search Within

Erin Biggar

Formats
  1. Meeting Abstract (4)
  2. Correspondence (1)
  3. Journal Article (1)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (6)
  5. Survivorship Research (5)
  6. Biostatistics Service (4)

More Groups

People
  1. Matthew Matasar (5)
  2. Anas Younes (4)
  3. Connie Batlevi (4)
  4. Venkatraman Seshan (4)
  5. Ahmet Dogan (3)
  6. Alison Moskowitz (3)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Blood (1)
  3. Blood Advances (1)
  4. Hematological Oncology (1)
  5. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. American Society of Hematology (2)
  3. Taylor & Francis Group (1)
  4. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL)
    Meeting Abstract

    Noy, A.; Hughes, S.; Biggar, E.; Bogdan, M.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save